# Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

> **NCT02989168** · PHASE2 · TERMINATED · sponsor: **Global Blood Therapeutics** · enrollment: 14 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Hypoxemia

## Interventions

- **DRUG:** GBT440

## Key facts

- **NCT ID:** NCT02989168
- **Lead sponsor:** Global Blood Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2017-10-23
- **Final completion:** 2017-10-23
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of clinically meaningful benefit
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02989168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02989168, "Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02989168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*